when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

← back to LILLY

News mentioning LILLY

793 stories

Aug 5, 26STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis findsstat

Aug 5, 264 potential biotech M&A targets, plus a pretty sure bet from J&Jbiospace

Aug 5, 26Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed datafiercebiotech

Aug 4, 26Novo dips 6% on Wegovy pill stumble despite Q2 earnings beatbiospace

Aug 4, 26Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surgesstat

Aug 4, 26STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plansstat

Aug 4, 26STAT+: Three biotechs with three news updatesstat

Aug 4, 26Novo vs. Lilly: Q2's cardiometabolic grudge matchendpoints

Aug 4, 26STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and morestat

Aug 4, 26Trans federal employees sue over revoked health coveragestat

Aug 4, 26STAT+: The latest orphan drug exemptions may not be warranted, analysis findsstat

Aug 4, 26STAT+: As Trump administration pushes court-ordered mental health care, a new report raises questionsstat

Aug 4, 26Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelcaraps

Aug 3, 26STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate casestat

Aug 3, 26STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drugstat

Aug 3, 26Curium strikes up to $8B deal for radiopharma rival Lantheusfiercebiotech

Aug 3, 26STAT+: Is there a pharma mega-merger in the making?stat

Aug 3, 26STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and morestat

Aug 3, 26STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with statesstat

Aug 3, 26STAT+: Are AI scribes useful tools in medical education, or a crutch that imperils learning?stat

Aug 2, 26STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricingstat

Jul 31, 26Trump administration tries again to institute rebates in 340Bbiopharma dive

Jul 31, 26STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitalsstat

Jul 31, 26Lilly and Resilience invest $750M in diabetes and obesity drug device supplybiospace

Jul 31, 26Resilience and Lilly invest $750M to boost Cincinnati drug productionbiopharma dive

Jul 31, 26Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%biospace

Jul 31, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Jul 31, 26STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and morestat

Jul 31, 26Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchfiercebiotech

Jul 30, 26Capricor’s data clash and a fugitive in the C-suitestat

← prevpage 16 of 27next →

LILLY · news · pharmadog